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Abstract
Background: The main objective of this study was to investigate the angiotensin converting
enzyme (ACE) genotype as a possible risk factor for migraine (both with and without aura)
compared to controls. We also wanted to examine whether a clinical response to an ACE inhibitor,
lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to
ACE genotype.
Methods: 347 migraine patients aged 18–68 (155 migraine without aura (MoA), 187 migraine with
aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years
of age were included in the study. A polymerase chain reaction (PCR) was performed on the
genomic DNA samples to obtain the ACE insertion (I)/deletion(D) polymorphisms.
Results: No significant differences between migraine patients and controls were found with regard
to ACE genotype and allele distributions. Furthermore, there was no significant difference between
the controls and the MwA or MoA subgroups.
Conclusion: In our sample there is no association between ACE genotype or allele frequency and
migraine. In addition, ACE genotype in our experience did not predict the clinical response to
lisinopril or candesartan used as migraine prophylactics.
Background
Two small open studies reported an improvement of the
headache in migraine patients using an angiotensin-con-
verting enzyme (ACE) inhibitor [1,2]. Indirectly, a benefi-
cial effect of angiotensin II receptor blockers (ARB's) on
headache is shown in a meta-analysis on side effects
reported in placebo controlled trials including over 12
000 patients [3]. Two randomized, placebo controlled
studies conducted by our research group have evidence for
efficacy of an ACE inhibitor (lisinopril) and an ARB (can-
desartan) in migraine prophylaxis [4,5]. This and other
evidence points in the direction of involvement of the
renin-angiotensin system (RAS) in migraine pathophysi-
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see reference [6]).
The human angiotensin converting enzyme (ACE) gene
consists of either an insertion (I) allele or a deletion (D)
allele forming three possible genotypes: II, ID or DD.
Many studies have suggested an association between the
ACE-D allele and cardiovascular diseases [7]. For migraine
an Italian (Paterna) [8], an Australian (Lea) [9], and a Jap-
anese (Kowa) [10] study has demonstrated different
results regarding whether an association between the ACE
polymorphisms and this condition exists (Table 1).
The objectives of the present study were two-fold. Firstly
we wanted to examine whether a beneficial effect in the
above mentioned migraine prophylactic studies [4,5]
could be predicted by ACE genotype, a question that has
also been raised in a recent publication [11]. Secondly we
wanted to investigate the ACE genotype as a possible risk
factor for migraine with (MwA) and without (MoA) aura
in a Norwegian population.
Methods
Included in the study were 347 migraine patients aged
18–68 (155 MwA, 187 MoA and 5 missing aura subgroup
data, based on ICHD-2 criteria [12]) and 403 healthy
non-migrainous controls > 40 years of age. The
migraineurs were recruited partly from the lisinopril [4]
(n = 49) and candesartan [5] (n = 59) studies, and the
remaining group (n = 239) from the outpatient clinic of
the Department of Neurology, Trondheim University
Hospital. The patients and the controls were recruited
from the same area and only subjects with Nordic ethnic
background were included. The diagnosis was confirmed
by an experienced clinical neurologist. Responder status
in the candesartan and lisinopril studies was defined as a
reduction in days with headache of at least 50% in the
treatment period compared to the placebo period. Non-
responders were the subjects not defined as responders
and with both genotype and response data available. No
patients were included in both the lisinopril and cande-
sartan studies. The control group was recruited in collab-
oration with the Department of Immunology and
Transfusion Medicine and criteria for inclusion were no
present or former history of migraine or other types of
chronic headaches, no history of epilepsy or of hyperten-
sion in need of medical treatment, and age > 40 years
(since status as "non-migraineur" cannot be determined
with relative certainty before this age). No direct interview
was made in the control group, but the participants filled
out a questionnaire to determine eligibility for participa-
tion. In addition to not having migraine the control group
was required to have no other headache condition and
less than one headache day per month.
The migraine group had a mean age of 41 years (standard
deviation (SD): ± 12 years) and consisted of 268 women
and 79 men. Median age of migraine onset was 16 years
Table 1: ACE genotype and allele distributions among controls and migraine patients in different studies
Genotypes Alleles
N DD(%) ID(%) II(%) D(%) I(%)
Controls
Tronvik 403 92 (26.6) 204 (50.6) 107 (22.8) 388 (48.1) 418 (51.9)
Paterna (ref 8) 201 75 (37.3) 101 (50.3) 25 (12.4) 251 (62.4) 151 (37.6)
Lea (ref 9) 244 76 (31.1) 122 (50.0) 46 (18.9) 274 (56.1) 214 (43.9)
Kowa (ref 10) 248 31 (12.5) 114 (46.0) 103 (41.5) 176 (35.5) 320 (64.5)
Migraine
Tronvik 347 78 (22.5) 186 (53.6) 83 (23.9) 342 (49.3) 352 (50.7)
Paterna 302 146 (48.3) 129 (42.7) 27 (9.0) 421 (69.7) 183 (30.3)
Lea 250 77 (30.8) 142 (56.8) 31 (12.4) 296 (59.2) 204 (40.8)
Kowa 176 33 (18.7) 86 (48.9) 57 (32.4) 152 (43.2) 200 (56.8)
MwA subgroup
Tronvik 155 34 (21.9) 87 (56.1) 34 (21.9) 155 (50.0) 155 (50.0)
Paterna NA NA NA NA NA NA
Lea 151 48 (31.8) 85 (56.3) 18 (11.9) 181 (59.9) 121 (40.1)
Kowa 54 14 (25.9)* 26 (48.2) 14 (25.9) 54 (50.0)* 54 (50.0)
MoA subgroup
Tronvik 187 43 (23.0) 96 (51.3) 48 (25.7) 182 (48.7) 192 (51.3)
Paterna 302 146 (48.3)* 129 (42.7) 27 (9.0) 421 (69.7) 183 (30.3)
Lea 99 29 (29.3) 57 (57.6) 13 (13.1) 115 (58.1) 83 (41.9)
Kowa 122 19 (15.6) 60 (49.2) 43 (35.2) 98 (35.2) 146 (59.8)
* Reported significant finding for genotype or allele frequenciesPage 2 of 5
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In the control group with 233 women and 170 men, mean
age was 50 years (SD: ± 7 years).
311 of the samples were genotyped by AstraZeneca, R&D
Genetics, UK, and 439 samples were genotyped at the
Department of Neurology, Trondheim University Hospi-
tal, Norway.
Genomic DNA preparation and polymerase chain reaction 
(PCR) analysis
DNA was extracted from peripheral EDTA-blood stored at
-80°C. The D and I alleles were identified on the basis of
PCR amplification of the respective fragments from intron
16 of the ACE gene. The oligonucleotide primers [13,14]
used (MedProbe) were sense (forward): 5' CTGGAGAC-
CACTCCCATCCTTTCT 3' and antisense (reverse): 5' GAT-
GTGGCCATCACATTCGTCAGAT 3'. Amplification was
performed with 0.5 μmol of each primer. The PCR prod-
uct was a 191 bp fragment in the absence, and a 479 bp
fragment in the presence of the insertion. Homozygous D
alleles were confirmed using the insertion-specific primer
5' TTTGAGACGGAGTCTCGCTC 3'.
Part of the samples (n = 311) were amplified using a ther-
mal cycler and the products separated on 2% agarose gel.
The remaining samples (n = 439) were analyzed using a
LightCycler instrument (Roche). Amplification condi-
tions for the first method were 1.2 mM MgCl2, 1 U Ampl-
iTaq Gold, 200 μM dNTPs and 5 μL DNA template in a
total reaction volume of 25 μL, enzyme activation at 94°C
for 20 min, denaturation at 94°C for 1 min, annealing at
58°C for 1 min and extension at 72°C for 2 min for a total
of 32 cycles. Samples analyzed by LightCycler used the
FastStart DNA Master SYBR Green 1 mix, which includes
Taq DNA polymerase (Roche Diagnostics), plus 3 mM
MgCl2, and 2 μL DNA template, in a total reaction volume
of 20 μL with enzyme activation at 95°C for 10 min,
denaturation at 95°C for 10 s, annealing at 50°C for 5 s,
and elongation at 72°C for 15 s, for a total of 35 cycles.
The fluorescence intensity of the double-strand specific
SYBR Green I is directly proportional to the amount of
PCR product formed. Melting curves indicated the respec-
tive melting temperatures of the 191 bp and 479 bp frag-
ments to be 84.5°C and 91.8°C respectively, with
samples from heterozygotes displaying a peak at both
temperatures. Reaction products were confirmed on 2%
agarose gel. The ratio between cases and controls was the
same for both methods of analysis and blinded control
experiments in 10 random patients analysed by the first
method were confirmed by the second method.
Statistical analysis
Observed genotype count was used to calculate genotype
and allele frequencies for the ACE I/D polymorphism. The
expected genotype proportions were calculated and com-
pared to the observed proportions according to the
Hardy-Weinberg law. The significance level was set at p <
0.05. For comparison between groups we used the χ2 test
with one or two degrees of freedom. To compare means
(age of debut, frequency of migraine/headache) we used
one-way ANOVA. Statistical analysis were performed
using SPSS version 13.0 for Windows (SPSS Inc., Chicago,
IL, USA). Power calculation for the association between
ACE polymorphisms and migraine was performed with
the method described by Altman with correction for une-
qual sample sizes [15]. For the association between ACE
polymorphisms and drug response, we performed a one
sample two tailed test with alpha = 0.05.
Ethics
The study was approved by the regional committee for
ethics in medical research, and by the Norwegian data
inspectorate. All subjects included gave a written
informed consent.
Results
The observed genotypes in the control population did not
deviate significantly from the Hardy-Weinberg equilib-
rium (p = 0.98). With regard to the genotype and allele
distributions, no significant differences between migraine
patients and controls were detected, even though the ACE-
D allele tended to be more frequent (p = 0.058) among
responders than non-responders in the candesartan group
(Table 2). Furthermore, there was no significant difference
between the controls and the MwA or MoA subgroups,
nor between responders and non-responders to lisinopril
and candesartan, and no difference was detected when
stratifying by sex. Within the migraine group differences
in genotype could not explain the presence of aura (n =
342, missing data = 5, p = 0.64), of coexisting tension-type
headache among migraineurs (n = 343, missing data = 4,
p = 1.0), differences in age of debut (n = 342, missing = 5,
p = 0.69) or frequency of migraine (n = 342, missing = 5,
p = 0.52) or in headache frequency as recorded in the pla-
cebo period in the candesartan study (n = 56, missing = 3,
p = 0.77).
Frequencies of the genotypes and alleles for the different
studies are presented in Table 1. There are large differences
in genotypes and alleles among the controls. E.g. the II
genotype varies between 12.4 and 41.5 and the D-allele
between 35.5 and 62.4%.
Discussion
In the present Norwegian sample, there is no difference in
ACE genotype or allele frequency in a migraine group
compared to a control group. Associations between ACE
polymorphism and migraine reported in other studies are
not consistent and have been detected in different diag-Page 3 of 5
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shown in Table 1. In addition a recently published study
from Taiwan found no differences in ACE allelic frequen-
cies between migraine patients and controls, but stratified
by gender the DD frequency was significantly lower in
male migraineurs than controls (not included in Table 1
because only the abstract was published in the English
language) [16]. Findings that the DD genotype is more
frequent in MoA [8] and MwA [10] or less frequent in
male migraineurs [16] are not supported by our data. Our
population which is the largest to date used to study the
relationship between ACE polymorphism and migraine
(MoA and MwA) should have >80% power to detect an
association of the same magnitude as in the study by
Paterna et al [8]. Our study also did not find a relationship
between ACE genotype and response to prophylactic
drugs influencing the RAS. The allele frequency in the
responders versus non-responders in the candesartan
group had a p-value of 0.058 and with low numbered
groups the risk of a false negative result is present.
The purpose of looking at the association between
responders in the two clinical trials and ACE genotype was
not to detect a small theoretical association, in which case
this subgroup analyses would be underpowered, but to
see whether there was an association so strong that it
would be valuable in clinical use predicting response in
migraine – prophylactic treatment. That is whether it
would be clinically beneficial to use ACE genotype to pre-
dict whether the patient would respond to the drug or not.
Our opinion is that in order for an association to be clin-
ical valuable at least 75–100% of responders to a
migraine-prophylactic drug should have a specific ACE-
genotype. The power of our study to measure a percentage
of 75% DD among the candesartan responders with the
control population as reference is > 80%.
A limitation of the study is that the control group was not
directly interviewed increasing the risk of migraineurs self-
reporting themselves as non-migraineurs and thereby
increasing the risk of type II errors. In order to minimize
this problem participants in the control group were
required to have no other headache condition and less
than one headache day per month.
Population stratification refers to differences in allele fre-
quencies between cases and controls due to systematical
differences in ancestry rather than in the association of
genes with disease [17,18]. There are large differences in
the frequencies of the ACE-alleles in different populations
(Table 1). Hence, due to the problem with population
stratification we did not find it meaningful to perform a
statistical analysis of the merged data of all these studies.
This might have been misleading also because the way
diagnosis were made, both of migraineurs and controls,
may differ somewhat between the studies.
Conclusion
There was no difference in ACE genotype distribution
between a migraine and a control population in our mate-
rial. Our study also indicates that ACE genotyping will not
be a valuable tool for predicting clinical response of drugs
influencing the angiotensin system in headache treat-
ment. It is, however, important that these findings should
be confirmed in other studies with more patients and
among different ethnic groups.
Abbreviations
RAS, renin-angiotensin system; ACE, angiotensin convert-
ing enzyme; MoA, migraine without aura; MwA, migraine
with aura; ARB's, angiotensin II receptor blockers.
Table 2: ACE genotype and allele distributions among controls and migraine patients in a Norwegian population
Genotypes Alleles
N DD(%) ID(%) II(%) D(%) I(%)
Controls 403 92 (26.6) 204 (50.6) 107 (22.8) 388 (48.1) 418 (51.9)
Migraine 347 78 (22.5) 186 (53.6) 83 (23.9) 342 (49.3) 352 (50.7)
MwA subgroup 155 34 (21.9) 87 (56.1) 34 (21.9) 155 (50.0) 155 (50.0)
MoA subgroup 187 43 (23.0) 96 (51.3) 48 (25.7) 182 (48.7) 192 (51.3)
Lisinopril responders 12 2 (16.7) 6 (50.0) 4 (33.3) 10 (41.7) 14 (58.3)
Lisinopril non-responders 37 10 (27.0) 16 (43.2) 11 (29.7) 36 (48.6) 38 (51.4)
Candesartan responders* 18 7 (38.9) 9 (50.0) 2 (11.1) 23 (63.9) 13 (36.1)
Candesartan non-responders* 38 8 (21.1) 18 (47.4) 12 (31.6) 34 (44.7) 42 (55.3)
Responders combined 30 9 (30.0) 15 (50.0) 6 (20.0) 33 (55.0) 27 (45.0)
Non-responders combined 75 18 (24.0) 34 (45.3) 23 (30.7) 70 (46.7) 80 (53.3)
* Response data available in 56 of 59 genotyped
Allele and genotype frequency distributions are not significantly different for any diagnostic groups (migraine, MwA, MoA) vs controls, or for 
responders vs non-responders (p > 0.05).Page 4 of 5
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